Zacks Research Predicts Amgen’s Q4 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Equities researchers at Zacks Research dropped their Q4 2024 earnings per share (EPS) estimates for Amgen in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $4.86 for the quarter, down from their previous forecast of $5.40. The consensus estimate for Amgen’s current full-year earnings is $19.52 per share. Zacks Research also issued estimates for Amgen’s Q3 2025 earnings at $5.22 EPS and Q3 2026 earnings at $5.44 EPS.

AMGN has been the topic of several other reports. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Robert W. Baird reaffirmed an “underperform” rating and set a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. Bank of America lifted their price objective on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $320.00 to $335.00 in a report on Wednesday, August 7th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $362.00 price target on shares of Amgen in a report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and a consensus target price of $333.57.

Amgen Stock Performance

NASDAQ:AMGN opened at $294.00 on Monday. The firm has a market capitalization of $158.03 billion, a PE ratio of 37.64, a PEG ratio of 2.63 and a beta of 0.60. The firm’s fifty day simple moving average is $315.69 and its 200 day simple moving average is $318.05. Amgen has a 1 year low of $260.68 and a 1 year high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.96 earnings per share.

Institutional Trading of Amgen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Synovus Financial Corp raised its stake in Amgen by 3.2% in the 3rd quarter. Synovus Financial Corp now owns 65,564 shares of the medical research company’s stock valued at $21,124,000 after acquiring an additional 2,046 shares during the period. Tidal Investments LLC grew its holdings in shares of Amgen by 2.7% during the 3rd quarter. Tidal Investments LLC now owns 24,480 shares of the medical research company’s stock worth $7,888,000 after purchasing an additional 646 shares in the last quarter. Wilmington Savings Fund Society FSB increased its holdings in Amgen by 9.7% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 65,201 shares of the medical research company’s stock valued at $21,008,000 after buying an additional 5,748 shares during the period. Arvest Bank Trust Division bought a new position in Amgen in the third quarter valued at approximately $408,000. Finally, World Investment Advisors LLC raised its holdings in shares of Amgen by 48.4% during the 3rd quarter. World Investment Advisors LLC now owns 11,083 shares of the medical research company’s stock worth $3,571,000 after buying an additional 3,616 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 3.06%. Amgen’s dividend payout ratio is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.